LifeVantage Corporation (LFVN)
Valuation Overview•Is LifeVantage Corporation Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Moderate quality score of 65/100, reflecting stable operating margins and manageable leverage.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Verdict: Solid fundamental quality, though growth presents a headwind.
Wall Street is cautious, forecasting potential downside alongside robust expected earnings growth. This outlook is strongly supported by highly attractive capital returns, driven by a balanced mix of reliable dividends and share buybacks.
LFVN demonstrates strong business quality with robust profitability and healthy margins (highlighted by a massive 37.5% ROIC). This is backed by a fortress balance sheet, holding significant net cash ($9M) and minimal debt risk.
The company exhibits steady, low-single-digit revenue growth paired with highly explosive earnings growth (46.8% EPS 3Y CAGR). However, profitability remains a major concern with severely compressed operating margins (3.4%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $43.7M | +14.2% | +3.5% | -0.4% | +1.8% | |
| EBITDA | $1.7M | — | +12.3% | — | — | |
| Net Income | $1.4M | +233.8% | +46.5% | — | +3.4% | |
| EPS (Diluted) | $0.11 | +230.4% | +46.8% | -0.8% | +4.5% | |
| Free Cash Flow | $4.0M | +5.6% | +17.8% | -7.7% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 78.1% | 79.8% | 80.7% | 82.0% |
| Operating Margin | 3.4% | 3.2% | 4.2% | 4.6% |
| Net Margin | 2.9% | 2.3% | 2.9% | 2.9% |
| FCF Margin | 1.9% | 3.8% | 3.5% | 4.1% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.16 | $0.12 | -25.0% | ||
| Q1'26 | $0.19 | $0.15 | -21.1% | ||
| Q4'25 | $0.17 | $0.18 | +5.9% | ||
| Q3'25 | $0.17 | $0.17 | +0.0% | ||
| Q2'25 | $0.16 | $0.26 | +62.5% | ||
| Q1'25 | $0.13 | $0.22 | +69.2% | ||
| Q4'24 | $0.15 | $0.15 | +0.0% | ||
| Q3'24 | $0.21 | $0.14 | -33.3% |
Total return is -47.8% (1Y), lagging the benchmark by -72.8%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +7.9% | -1.4% | — |
| 1Y | -47.8% | -72.8% | +1.5% |
| 3YCAGR | +13.4% | -8.0% | +17.9% |
| 5YCAGR | +0.2% | -14.0% | +14.2% |
| 10YCAGR | -5.8% | -19.4% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about LifeVantage Corporation (LFVN) valuation, health, and returns.
Based on peer relative multiples, LifeVantage Corporation appears Cheap versus peers compared to industry peers.
LifeVantage Corporation has multiple valuation anchors: Peer Relative Fair Value: $7.87 | Wall Street Analyst Target: $5.00 (implying -22.0% upside). A convergence of these signals offers higher conviction.
LifeVantage Corporation displays good financial health with a composite quality score of 65/100, supported by a Altman Z-Score of 2.8 (grey zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 37.5%.
LifeVantage Corporation pays a 2.5% dividend yield, covered by a 21% payout ratio with 4 years of growth, supplemented by a 7.2% buyback yield.
LifeVantage Corporation's current growth trajectory is Accelerating. The company achieved +14.2% 1Y revenue growth and +230.4% 1Y EPS growth, compared to its 3Y revenue CAGR of +3.5%.
Wall Street consensus is Hold based on 3 analysts, beating EPS expectations in 42% of recent quarters with a -2-quarter streak. The consensus price target represents a -22.0% change from current levels.
Investment risks for LifeVantage Corporation include: -72.3% 1-year max drawdown. Volatility risk is characterized by a beta of 0.91x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.